High-sensitivity cardiac troponin T (hs-cTnT) is a biomarker used in diagnosing myocardial injury. The clinical utility and the variation of this biomarker over time remain unclear in hemodialysis (HD) and peritoneal dialysis (PD) patients. We sought to determine whether hs-cTnT concentrations were predictive of myocardial infarction (MI) and death and to examine hs-cTnT variability over a 1-year period.
Mortality remains high, approaching 15%-20% annually, for patients with end-stage renal disease and those undergoing renal replacement therapy (1, 2 ) . The primary cause of death, although decreasing, continues to be cardiac and accounts for 39%-45% of all-cause mortality (1) (2) (3) . Identifying which patients are at greater risk of cardiac mortality and would benefit from targeted management continues to be a challenge and a source of controversy. In this setting, risk stratification could be a valuable clinical tool to assist in identifying and targeting this high-risk group.
Serum biomarkers can aid in risk stratification. Biomarkers such as C-reactive protein (CRP) 4 (4 ) and albumin (5 ) have been validated to predict mortality in the stable dialysis population. Serum assays of cardiac biomarkers similarly play important roles, with cardiac troponin I and cardiac troponin T predicting all-cause mortality (4, 6, 7 ) , myocardial infarction (MI) (6 ) , and cardiac abnormalities on coronary angiogram (4 ) in the stable dialysis population.
Consensus guidelines for diagnosing acute MI have led to the development of a generation of assays with enhanced clinical sensitivities that are now easily available for clinical use. The fifth-generation highsensitivity cardiac troponin T (hs-cTnT) test provides high assay precision at the 99th percentile of the normal reference population (8 ) . In the non-renal disease population, hs-cTnT assays have been shown to detect myocardial injury earlier (9 -13 ) and identify more patients at risk of future adverse outcomes than conventional assays (10, 14 ) .
However, the role of hs-cTnT as a prognostic serum biomarker in the stable dialysis population, i.e., patients on hemodialysis (HD) and peritoneal dialysis (PD), has still not been fully explored. This is particularly true for patients on PD. Similarly, we lack information on prospective changes in hs-cTnT concentrations over time in stable dialysis patients. We therefore conducted a prospective observational analysis of all stable dialysis patients to determine the utility of these cardiac biomarkers for identifying patients at high risk for a new MI or death, to explore the importance of hs-cTnT in the PD population, and to examine the variability of hs-cTnT in the dialysis population over a 1-year period.
Material and Methods

STUDY POPULATION
We report a prospective, single-center observational study. A total of 431 patients Ն18 years of age and undergoing HD or PD for more than 2 weeks in a tertiary care facility (Liverpool Hospital, NSW, Australia) and its satellite services were identified. hs-cTnT was performed on July 2011 on all stable dialysis patients, with HD patients having both a pre-HD and post-HD measurement. Patients were excluded if they were acutely unwell, requiring inpatient hospital management in the week before the hs-cTnT, if no hs-cTnT was performed, or if they were pregnant. This study was approved by the South Western Sydney Local Health District Human research ethics committee (LNR/12/LPOOL/359).
Sociodemographic, clinical, and laboratory data were obtained at the time of the initial blood test. These included sex, age (years), previous history of diabetes (type I or type II), cardiac disease, hepatitis B/C, deep vein thrombosis (DVT), pulmonary embolism (PE), or peripheral vascular disease (PVD). Laboratory parameters, including serum albumin (g/dL), corrected cal-
, CRP (mg/L), and parathyroid hormone (PTH) [pg/mL (pmol/L)] were obtained for each patient during a nonacute phase within 4 weeks of the initial hs-cTnT assay. After a 1-year period, hscTnT was repeated in all surviving nonacute patients. We calculated dialysis vintage as the total number of years on dialysis subtracting the time a functional transplant was present. Dialysis adequacy was calculated using dialyzer clearance of urea ϫ dialysis time/ volume of body fluid (Kt/V) (single pool). For HD patients, the mean of 3 readings on separate days during the month was calculated. Patients on PD had a single measurement of Kt/V.
BLOOD COLLECTION FOR hs-cTnT ASSAY
Blood samples were obtained using a 5-mL serum separator gel tube (Greiner Bioone) before initiating HD, immediately on completing HD, or during an outpatient visit for PD patients. hs-cTnT was measured using a fifth-generation electrochemiluminescence assay (Elecsys, Cobas e602 analyzer, Roche Diagnostics) and performed in a laboratory accredited by the National Association of Testing Authorities, Australia. According to the manufacturer of the assay, the stated limit of detection is 5 ng/L, the analytical range is 3-10 000 ng/L, and the upper reference limit (99th percentile) in the normal population is 14 ng/L. The CV is Ͻ10% at the lowest concentration of 13 ng/L. After 1 year, hscTnT measurement was repeated.
DEFINITIONS
A post-hs-cTnT MI was defined as an MI after the hs-cTnT assay was obtained. An MI was identified by a rise in hs-cTnT (defined as a Ͼ20% increase from a previous baseline) in addition to symptoms of ischemia, new electrocardiographic changes (significant ST segment T-wave changes, new left bundle branch block, or development of pathological Q waves on electrocardiogram), or identification of an intracoronary thrombus by angiography per the new consensus definition for MI (8 ) . Diagnosis was confirmed and managed by the in-hospital cardiologist. We also obtained and documented any history of pre-hs-cTnT MI based on the same criteria. A fatal MI was a mortality resulting from an MI. The time to an event was defined as the time (in weeks) from the date the hs-cTnT was obtained until the day of the outcome or event.
PATIENT GROUPS AND OUTCOMES
Patients were divided into quartiles for hs-cTnT. In the HD group, 5 patients had hs-cTnT post-HD but not pre-HD. They were included in the analysis of data but not in the quartile or multivariate analysis. A comparison of comorbidities, laboratory parameters, and outcomes was then performed between the HD and PD groups and between the quartiles.
Outcomes were analyzed for (a) death from any cause and time to death, (b) MI and time to MI, (c) a combined end point of MI and death, and (d) change in hs-cTnT after a 1-year interval. Patients were censored from further follow-up if they underwent kidney transplantation.
STATISTICAL METHODS
Categorical data are expressed using frequency (%) and were compared using the 2 test. Continuous data are expressed as medians with interquartile ranges (IQR) (25th-75th percentile) or mean with SD and were compared by the Student t-test or Mann-Whitney U-test as appropriate. Data were compared across quartiles by use of 2 , ANOVA, and Kruskall-Wallis tests, as appropriate. Kaplan-Meier time-to-event curves, followed by a log-rank test, were generated to evaluate differences in outcome by quartile. Cox proportional hazard models were used to calculate unadjusted HRs (uHRs) and adjusted HRs (aHRs) for outcomes analyzing hs-cTnT as a continuous variable. In multivariable analysis, we adjusted for important clinical variables associated with outcomes in the univariate analysis. We used logistic regression analysis to calculate predictor probabilities of an event for each patient. The models used were clinically relevant covariates alone and in addition to hs-cTnT. ROCs and the area under the curve (AUC) were used to evaluate the prognostic value of these scores in addition to hs-cTnT alone for outcomes. We evaluated the statistical significance of differences in the AUCs for clinical variables with and without addition of hs-cTnT (15 ) . For comparison between hs-cTnT at baseline and after 1 year we used Wilcoxon signed-rank tests. All statistical analyses were performed using SPSS version 19.0. A P value of Ͻ0.05 was considered significant. 
Results
STUDY POPULATION AND OUTCOMES
A total of 317 HD patients were identified and 44 were excluded (35 patients had no hs-cTnT performed, 8 were acutely unwell at the time of the study, and 1 patient was pregnant). A total of 114 PD patients were identified and 26 were excluded (20 had no hs-cTnT performed and 6 were acutely unwell). The final population study comprised 393 patients, 275 on HD and 118 on PD.
Baseline demographic and clinical and laboratory data for patients are presented in Table 1 No patients were lost to follow-up. The median hs-cTnT in our stable dialysis population was 57 ng/L (IQR, 36 -101 ng/L). Only 3.5% of patients had hs-cTnT Ͻ14 ng/L, the upper reference end point for the normal population (Fig. 1 ). There was a high prevalence of previous MI (27.2%). Patients with a previous MI had higher hs-cTnT at baseline in comparison with those without (75 ng/L vs 56 ng/L, P ϭ 0.001).
We followed our patients for a period of 59 weeks (IQR, 59 -60 weeks). The combined end point of death/MI was reached in 18.6% of patients. During this interval a new MI occurred in 8.9% of patients and this group had a higher hs-cTnT at baseline compared with patients who did not have a new MI (97 ng/L vs 56 ng/L, P Ͻ 0.001). The mortality was 12.7%, and these patients also had a higher hs-cTnT at baseline (95 ng/L vs 55 ng/L, P Ͻ 0.001). Fatal MIs accounted for 25.5% of deaths. Table 1 provides a summary of baseline demographic, clinical, and laboratory values and outcomes in the HD and PD groups. No statistically significant differences were found between patients undergoing HD and those on PD for hs-cTnT (60 ng/L vs 55 ng/L, P ϭ 0.11).
HD vs PD
In the HD group there was a statistically, but not clinically, significant reduction in hs-cTnT from pre-HD to post-HD concentrations (60 ng/L vs 58 ng/L, P Ͻ 0.001).
hs-cTnT was increased at baseline, similarly to the overall study group, in patients who developed new MI in the HD group (91 ng/L vs 58 ng/L, P ϭ 0.017) and in the PD population (116 ng/L vs 51 ng/L, P ϭ 0.001). This trend was also true for mortality in the HD group (92 ng/L vs 57 ng/L, P ϭ 0.005) but not the PD group (116 ng/L vs 52 ng/L, P ϭ 0.058).
DIVIDING STUDY GROUP INTO QUARTILES
We divided our group into quartiles based on hs-cTnT concentrations ( Table 2 ). Across quartiles there was an increase in age (P Ͻ 0.001), history of diabetes (P Ͻ 0.001), cardiac disease (P ϭ 0.001), Kt/V (P ϭ 0.04), and dialysis vintage (P Ͻ 0.001). Sex (male) also differed across the quartiles, increasing from 43.9% in the first quartile to 79.2% in the fourth (P Ͻ 0.001). No statistical differences were seen across quartiles for albumin (P ϭ 0.22) or CRP concentrations (P ϭ 0.21) or hemoglobin levels (P ϭ 0.82). There were a significant increases in the incidences of MI (P ϭ 0.001) and mortality (P ϭ 0.024) and the combined end point (P Ͻ 0.001) across quartiles.
In the HD and PD groups there were similar trends across the hs-cTnT quartiles for age (HD and PD, P Ͻ 0.001 and P ϭ 0.048, respectively), diabetes (HD and PD, P Ͻ 0.001 and P ϭ 0.001, respectively), cardiac disease (HD and PD, P ϭ 0.027 and P ϭ 0.046, respectively), and sex (HD and PD, P Ͻ 0.001 and P ϭ 0.025, respectively). CRP was the only other variable found significantly different across quartiles in the HD group (P ϭ 0.043). For PD patients Kt/V was the only other variable found significantly different across quartiles (P ϭ 0.016).
As the pre-HD hs-cTnT increased across the quartiles in the HD population so did the post-HD hscTnT. hs-cTnT was found to have decreased immediately post-HD, with the absolute decrease ranging from 2 ng/L in the first quartile to 14 ng/L in the fourth (P Ͻ 0.001). However, the relative percentage decrease did not differ across quartiles (range, 9.1%-10.8%; P ϭ 0.89).
In both the HD and the PD groups there were a statistically significant increases across quartiles for MI (P ϭ 0.012 and P ϭ 0.025, respectively) and the combined end point (P ϭ 0.001 and P ϭ 0.029, respectively). Mortality significantly increased in the HD group across quartiles (P ϭ 0.015) but not in the PD group (P ϭ 0.053). The dotted line represents 14 ng/L, below which is the reference range for the normal population. Quartiles based on number in the entire study group.
We constructed Kaplan-Meier curves to assess outcomes across quartiles based on hs-cTnT (Fig. 2) . With increasing hs-cTnT quartiles, the incidence of mortality (P ϭ 0.001) and new MI (P ϭ 0.001) and the combined end point (P Ͻ 0.001) also increased. Similar findings were seen in HD patients for new MI (P ϭ 0.006 by log-rank test across quartiles of hs-cTnT), mortality (P ϭ 0.003), and the combined end point (P ϭ 0.001). For PD patients a significant trend was observed across quartiles for new MI (P ϭ 0.003) and the combined end point (P ϭ 0.023) but not for mortality alone (P ϭ 0.093).
UNADJUSTED AND ADJUSTED HRs FOR hs-cTnT
Univariate analyses were performed with Cox proportional hazards analysis to determine the uHR of vari- 
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ables associated with a statistically significant impact on outcomes (see Table 1 in the Data Supplement that accompanies the online version of this report at http:// www.clinchem.org/content/vol60/issue2). In the whole group, with hs-cTnT examined as a continuous variable, for every increase of 25 ng/L the uHR for mortality was 1.10 (95% CI, 1.04 -1.16; P ϭ 0.001), for MI was 1.16 (95% CI, 1.08 -1.23; P Ͻ 0.001), and for the combined end point was 1.13 (95% CI, 1.07-1.18; P Ͻ 0.001). The same trend was observed for mortality in HD patients (uHR, 1.09; 95% CI, 1.01-1.18; P ϭ 0.028) and in PD patients (uHR, 1.14; 95% CI, 1.04 -1.23; P ϭ 0.003). For MI this also was true in PD patients (uHR, 1.21; 95% CI, 1.11-1.31; P Ͻ 0.001) but not in HD patients (uHR, 1.08; 95% CI, 0.97-1.20; P ϭ 0.14). Using the combined end point, the uHR in HD patients was 1.08 (95% CI, 1.01-1.16; P ϭ 0.03) and in PD patients was 1.19 (95% CI, 1.17-1.28; P Ͻ 0.001).
A multivariate model was constructed to determine the effects of increasing hs-cTnT concentrations on mortality, MI, and the combined end point (Fig. 3) . Variables shown to be significant in univariate analysis were incorporated in the model to provide aHRs. In all the study groups, as hs-cTnT increased there was a significant risk of mortality (aHR, 1.07; 95% CI, 1.003-1.15; P ϭ 0.04), new MI (aHR, 1.14; 95% CI, 1.06 -1.22; P Ͻ 0.001), and for the combined end point (aHR, 1.10; 95% CI, 1.04 -1.17; P ϭ 0.001). This was similar for PD patients for mortality (aHR, 1.15; 95% CI, 1.04 -1.27; P ϭ 0.008), MI (aHR, 1.21; 95% CI, 1.11-1.33; P Ͻ 0.001), and the combined end point (HR, 1.21; 95% CI, 1.09 -1.34; P Ͻ 0.001). In the HD group, no statistical significance was found after adjustments for mortality (aHR, 1.03; 95% CI, 0.93-1.14; P ϭ 0.52), MI (aHR, 1.05; 95% CI, 0.92-1.20; P ϭ 0.44), or using a combined end point (aHR, 1.04; 95% CI, 0.95-1.14; P ϭ 0.40).
ROC CURVE ANALYSES
ROC curve analysis was used to predict outcomes over a 1-year period for hs-cTnT, a composite of clinical variables, and a combination of hs-cTnT and clinical variables (see online Supplemental Table 2 ). The clinical variables chosen were those with a significant impact on outcomes and included age, cardiac history, albumin, CRP, dialysis vintage, and a history of previous MI. For hs-cTnT alone, the AUC for mortality for all the groups was 0.65 (95% CI, 0.57-0.74; P ϭ 0.001), for the HD group 0.63 (95% CI, 0.54 -0.72; P ϭ 0.006), and for PD patients 0.70 (95% CI, 0.46 -0.94; P ϭ 0.058). As a predictor of MI, the AUC for all the groups was 0.70 (95% CI, 0.62-0.78; P Ͻ 0.001), for the HD group, 0.65 (95% CI, 0.55-0.74; P ϭ 0.015), and for the PD group 0.81 (95% CI, 0.69 -0.93; P ϭ 0.001). For the combined end point, the AUC for all the groups was 0.63 (95% CI, 0.56 -0.70; P Ͻ 0.001), for the HD group 0.67 (95% CI, 0.59 -0.76; P ϭ 0.02), and for PD patients 0.78 (95% CI, 0.61-0.96; P ϭ 0.001).
We then prepared ROC curves using a composite of hs-cTnT and clinical variables. With the use of this model, the AUC for all the study groups for mortality was 0.75 (95% CI, 0.67-0.83; P Ͻ 0.001), for MI 0.74 (95% CI, 0.65-0.82; P Ͻ 0.001), and for the combined end point 0.70 (95% CI, 0.64 -0.76; P Ͻ 0.001).
hs-cTnT VALUES OVER 1 YEAR
We examined changes in hs-cTnT in 261 patients (68 PD patients and 193 HD patients) who survived and had hs-cTnT retested after 1 year [median, 0.99 years (IQR, 0.991-0.996)]. hs-cTnT at baseline for this patient group was 55 ng/L (IQR, 31-94). After 1 year the repeat hs-cTnT in this overall group was not found to be significantly different (P ϭ 0.22) at 53 ng/L (IQR, 34 -86) (see online Supplemental Fig. 1 ). Similar findings were seen in PD patients with hs-cTnT at baseline of 46 ng/L (IQR, 26 -79) and after 1 year of 51 ng/L (IQR, 28 -87); P ϭ 0.10. However, in HD patients there was a statistically significant reduction in hscTnT from a baseline of 56 ng/L (IQR, 36 -96) to a 1-year concentration of 53 ng/L (IQR, 35-86); P ϭ 0.028.
We divided the patients with a repeat hs-cTnT into 2 groups, those who did or did not develop an MI in the intervening year (Fig. 4) . We observed no change in hs-cTnT in either group when we compared baseline hs-cTnT values to results after 1 year, even in those who subsequently developed an MI.
Discussion
In this prospective study of consecutive HD and PD patients, we evaluated the utility of hs-cTnT as a predictor of adverse events over a 1-year period. Earlier studies that examined serum biomarkers in patients with end-stage kidney disease were limited to using the older troponin T assays (third and fourth generation) and confirmed that troponin T was one of the better markers for predicting adverse events (16 aHR values were calculated using variables found to have a statistically significant effect on outcome on the univariate analysis. Factors used in determining the aHR model include: all group MI: age, history of cardiac disease, thromboembolism, dialysis vintage, and previous cardiac events; mortality: age, history of cardiac disease, malignancy, albumin, and CRP; HD group MI: age, history of cardiac disease, albumin, and previous cardiac events; mortality: age, history of cardiac disease, malignancy, and albumin; PD group MI: age, albumin, and dialysis vintage; mortality: adjusted for age, history of malignancy, albumin, and dialysis vintage. For the combined end points, factors used were age, history of cardiac disease, albumin, CRP, dialysis vintage, and previous cardiac events. a more sensitive assay, hs-cTnT (fifth generation) has been developed. We report 4 major findings using this assay. First, hs-cTnT is useful for predicting mortality and MI in this population, with a divergence appearing as early as 12 months. Second, hs-cTnT appears useful in patients undergoing PD, a patient group that has been neglected classically. Third, the concentration of hs-cTnT appears to be proportionally reduced post HD. Finally, the hs-cTnT concentration appears to be stable over a 1-year period even in patients who sustained a new MI.
We found a higher proportion of dialysis patients (96.4%) with hs-cTnT concentrations above the reference interval of the healthy population, results in agreement with previous studies (17, 18 ) . This is a marked difference compared to studies of older troponin T assays, in which only 15% to 45% of patients on dialysis were found to have increased concentrations (7, 19 -24 ) . The greater sensitivity of the hs-cTnT assay has been shown to improve our ability to diagnose MI, in comparison with the older assays, in the non-renal disease population (11) (12) (13) (14) . In line with our current data, hs-cTnT also appears to be a better predictor of outcome than the older assays for patients on dialysis (25 ) .
We demonstrated that hs-cTnT is an effective marker for adverse events after only 12 months of follow-up. Smaller studies of troponin T as a predictor of adverse events using longer follow-up (15-24 months) found AUCs from ROC curve analysis to be 0.7-0.85 (20, 22 ) . Larger studies found AUCs of 0.67 after 2-3 years of follow-up (7, 23 ) . Studies for hscTnT demonstrate AUCs of 0.68 -0.76 after 2-4 years of follow-up (18, 25 ) . Such findings agree with our data, but our data have established the utility of hscTnT as early as 12 months. hs-cTnT also had a higher sensitivity than earlier troponin T assays. This enhanced sensitivity may lead to better risk stratification of patients, allowing us to better identify those at risk of an MI or mortality as demonstrated in our analysis.
In this analysis, we established for the first time the proportional reduction in hs-cTnT post-HD. hs-cTnT is known to decrease post-HD (17 ) . We have shown this to be a concentration-dependent relationship, with an overall reduction of 10% from pre-HD values regardless of baseline hs-cTnT concentrations. However, a few areas of ambiguity still exist. It is known that troponin T concentrations are inversely related to renal function (26, 27 ) . A similar relation may exist in dialysis patients, because those who dialyze longer and achieve higher Kt/V exhibit a greater reduction in hscTnT. We also found a subgroup of patients (n ϭ 33, 12%) who exhibited an increase in hs-cTnT post-HD. We could not establish an association between these patients and an increased risk of MI or mortality. The significance of this finding remains to be clarified.
We demonstrated that hs-cTnT remains stable in both the HD and PD population over a 1-year period and more importantly that patients who suffered an MI did not have an increase in year-on-year concentrations. Previous long-term follow-up studies conducted with early troponin T assays similarly have shown no change over a 1-year period (21 ) . One study examined hs-cTnT in the HD population; however, it was limited by small numbers, exclusion of PD patients, and a short follow-up period of 3 weeks (17 ) . No study has prospectively examined changes in hs-cTnT following an MI in this population of patients. Based on the evidence from our study, hs-cTnT would be useful to establish a baseline and to assist in managing acute patients with an MI. Whether there are changes in hs-cTnT after more than a year still needs to be clarified.
Our data strengthen evidence that an increased hscTnT at baseline is a marker of MI and mortality in the stable dialysis population, independent of other risk factors. Previous analyses established this relationship but were limited by the use of earlier assays for troponin T (7, (22) (23) (24) 28 ) . We note a paucity of evidence from examination of hs-cTnT in the PD population. Several studies in this population using earlier generation assays for troponin T all confirm the association between increased concentrations and an increased risk of mortality and MI (5, 23, 24, 29 ) . One study examined hs-cTnT in this group but was limited by small numbers (n ϭ 30) (25 ) . In our study, we included PD patients to confirm the utility of hs-cTnT in this group as an effective marker for MI and mortality.
There are several strengths of our study. First there was no loss of patients to follow-up over a 1-year period. Moreover, we included PD patients because this is a group traditionally understudied. Furthermore, we repeated hs-cTnT measurements to examine and establish longitudinal relationships over a period of 1 year and included patients who sustained an MI in the analysis.
A limitation of our study was the conservative nature for our definition of fatal MI. It did not take into account sudden cardiac death or unwitnessed events occurring outside the hospital setting, which could have underestimated the true incidence of cardiac mortality. We also did not take into account patients on PD or HD who may have been on a different dialysis modality in the past or could have changed modality over the 1-year follow-up period. Lastly 1-year follow-up of hs-cTnT was not based on 1-year data in all patients.
In conclusion, hs-cTnT is a sensitive assay which has the potential for use as a predictive cardiac biomarker to identify high-risk patients. It is applicable in both HD and PD patients and its concentrations remain stable after 1-year follow-up. A prospective longitudinal study will be required to determine if active intervention for patients identified to be at high risk with this biomarker offers any benefit for long-term survival.
